-
Published10/06/2025
-
Today10/07/2025
-
Deadline31/08/2027
-
Opening of tenders31/08/2027
Utilities
- indicates text translated automatically in your browsing language
Open House Biologics Discount Contracts 2025-18 - Insulin glargine (Power: 100 U/ml) Text automatically translated in your browsing language Automatically translated
The aim of the participating coffers is to conclude discount agreements with all suitable pharmaceutical entrepreneurs pursuant to Section 130a(8) of the German Social Code (SGB V) on the active substance insulin glargine (power: 100 U/ml) to close. The contract is concluded within the framework of the open-house biologics procedure of the participating cash registers: Individual negotiations on contract contents are not conducted, uniform conditions apply. The participating health insurance companies do not guarantee any exclusivity to individual contractual partners. The contract period is a maximum of 24 months starting on 01.09.2025 (discount start at hkk is deviating from 01.10.2025). The contract ends no later than 31.08.2027, regardless of the date of conclusion of the contract. All further information can be found in the participation and contract documents. Text automatically translated in your browsing language Automatically translated
tdf-non-av
HEK - Hanseatische Krankenkasse
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.